ANI Pharmaceuticals FY Conference Summary Company Overview - ANI Pharmaceuticals is a profitable high-growth biopharmaceutical organization focusing on rare diseases, projecting over $1 billion in sales for 2026 with significant growth expected [2][22] - The company reported a 44% year-over-year growth in 2025, with a projected growth of 23% for 2026 [2][22] Core Business Segments Rare Disease Business - The rare disease segment is expected to represent about 60% of total company revenues in 2026, with projected sales of $618 million to $658 million, reflecting a 51% growth from 2025 [2][9] - Cortrophin Gel, the lead asset, is anticipated to grow 55% to 65%, reaching $540 million to $575 million in 2026 [8][22] - The rare disease business has shown an 84% growth in 2025, driven by key specialties including neurology, rheumatology, nephrology, and pulmonology [4][9] Generics Business - The Generics segment achieved a 28% year-over-year growth in 2025, supported by strong R&D capabilities and operational execution [5][18] - The company plans to maintain a cadence of 10 to 15 new product launches annually and invests a high single-digit percentage of Generics revenue into R&D [6][19] Strategic Priorities for 2026 1. **Accelerate Transformation into Rare Disease Company**: Focus on maximizing growth opportunities for Cortrophin Gel and expanding into under-penetrated specialty indications [5][12] 2. **Continue Execution on Generics Business**: Leverage operational excellence and R&D capabilities to enhance cash generation [6][19] 3. **Disciplined Capital Allocation**: Explore opportunities for inorganic growth in the rare disease sector while investing in Generics R&D [6][21] Market Dynamics - The ACTH market, which includes Cortrophin, is projected to approach $1 billion in sales by 2025, with a 45% year-over-year growth [10] - The company has identified significant unmet needs in various indications, with a focus on severe acute gouty arthritis flares, representing an addressable population of approximately 285,000 patients [11][12] Financial Performance - ANI Pharmaceuticals reported $883 million in revenues for 2025, with adjusted non-GAAP EBITDA of $230 million, reflecting a 47% year-over-year growth [4][22] - The company enters 2026 with over $286 million in cash and a net leverage of 1.5 times debt, indicating strong financial health [21][22] Conclusion - ANI Pharmaceuticals is well-positioned for long-term growth, leveraging cash flows from its Generics business to fuel investments in its rare disease segment, aiming to transform into a leading rare disease company [20][22]

Financial Data and Key Metrics Changes - In 2025, ANI Pharmaceuticals achieved record revenues of $883.4 million, representing a 44% year-over-year increase [12][42] - Adjusted non-GAAP EBITDA for the full year was $229.8 million, up 47% compared to the previous year [52] - Adjusted non-GAAP diluted EPS for 2025 was $7.89, compared to $5.20 in 2024 [51] Business Line Data and Key Metrics Changes - Cortrophin Gel revenues reached $347.8 million for the full year, a 76% increase year-over-year, driven by strong adoption across various specialties [43] - The generics business generated $384.1 million in revenue for 2025, reflecting a 28% increase year-over-year [44] - ILUVIEN net revenues were $74.9 million for the full year, with fourth-quarter revenues of $19.8 million [43] Market Data and Key Metrics Changes - The ACTH market approached $1 billion in sales in 2025, with expectations for significant growth in 2026 [27] - The addressable patient population for gouty arthritis in the U.S. is approximately 10 million, with only about 36% receiving treatment annually [28] Company Strategy and Development Direction - ANI's strategic priorities for 2026 include transforming into a leading rare disease company, executing in the generics business, and maintaining disciplined capital allocation [14][19] - The company plans to maximize the growth opportunity for Cortrophin Gel by expanding its reach in under-penetrated specialty indications [15] - A dedicated 90-person organization is being built to target acute gouty arthritis flares, aiming to capture a significant market opportunity [16][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $1 billion in revenue for 2026, with rare disease expected to account for approximately 60% of total revenues [20][66] - The company anticipates adjusted EBITDA growth of 23% year-over-year at the midpoint of guidance for 2026 [21] - Management noted that the ACTH market remains under-penetrated, providing a significant multi-year growth opportunity for Cortrophin [72][124] Other Important Information - ANI ended 2025 with $285.6 million in unrestricted cash, up from $144.9 million at the end of 2024 [53] - The company expects adjusted gross margin to be between 59.3% and 60.3% in 2026, slightly down from 2025 due to higher sales of royalty-bearing products [63] Q&A Session Summary Question: What is the multi-year opportunity for Cortrophin? - Management believes there is a significant multi-year growth opportunity for Cortrophin due to under-penetrated patient populations across indications [71][72] Question: How will the royalty structure impact gross margins? - The blended royalty rate for 2026 is anticipated to be in the high 20s, which will affect gross margins [75] Question: What is the expected operating leverage with the new sales force? - Management indicated that while they are investing in growth, they expect to maintain EBITDA margin percentages despite increased operating expenses [80] Question: What is the duration of treatment across different indications? - Duration of treatment varies, with sarcoidosis requiring more vials per patient compared to acute gouty arthritis flares [85] Question: How is the market access for ILUVIEN evolving? - Management noted that there have not been material changes in patient access, and they are focusing on alternative access channels to navigate market challenges [101][115]

Financial Data and Key Metrics Changes - In Q4 2025, ANI Pharmaceuticals recorded revenues of $247.1 million, a 30% increase year-over-year, and full-year revenues reached $883.4 million, up 44% compared to 2024 [21][22] - Adjusted non-GAAP EBITDA for Q4 was $65.4 million, up 31% year-over-year, and for the full year, it was $229.8 million, reflecting a 47% increase [26] - Adjusted non-GAAP diluted earnings per share for Q4 was $2.33, compared to $1.63 in the prior year, and for the full year, it was $7.89, up from $5.20 [26] Business Line Data and Key Metrics Changes - Cortrophin Gel revenues in Q4 were $111.4 million, an 88% increase year-over-year, and full-year revenues were $347.8 million, up 76% [21][22] - The generics business generated $100.8 million in Q4, a 28% increase, and full-year revenues were $384.1 million, also up 28% [22] - ILUVIEN net revenues were $19.8 million in Q4 and $74.9 million for the full year [22] Market Data and Key Metrics Changes - The ACTH market approached $1 billion in sales in 2025 and is expected to grow significantly in 2026, with Cortrophin Gel projected to grow by 55%-65% [13] - The addressable patient population for gouty arthritis is approximately 10 million in the U.S., with only 36% receiving treatment annually [14] Company Strategy and Development Direction - ANI's strategic priorities for 2026 include transforming into a leading rare disease company, executing in the generics business, and maintaining disciplined capital allocation [10][11] - The company plans to maximize the growth opportunity for Cortrophin Gel by expanding its reach in nephrology, neurology, rheumatology, ophthalmology, and pulmonology [8][9] - A dedicated 90-person organization will focus on acute gouty arthritis flares to capture additional market opportunities [9][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the multi-year growth potential for Cortrophin, emphasizing the under-penetrated patient populations across various indications [38] - The company anticipates delivering over $1 billion in revenue for 2026, with rare disease expected to account for approximately 60% of total revenues [11][34] - Management noted that the first quarter of 2026 may see a sequential decline in Cortrophin revenues due to typical seasonality but expects significant growth in subsequent quarters [29][30] Other Important Information - ANI ended Q4 2025 with $285.6 million in unrestricted cash, up from $144.9 million at the end of the previous year [26] - The company has a gross leverage of 2.7 times and a net leverage of 1.5 times its full-year adjusted non-GAAP EBITDA [27] Q&A Session Summary Question: What is the multi-year opportunity for Cortrophin? - Management believes in significant multi-year growth opportunities for Cortrophin, highlighting under-penetrated patient populations and ongoing investments in commercial initiatives [38][39] Question: How will the royalty structure affect gross margins? - The blended royalty rate is expected to be in the high 20s for 2026, following the company surpassing the highest royalty tier in 2025 [39] Question: What is the expected operating leverage with the new sales force? - Management indicated that while they are investing in growth, they expect to maintain EBITDA margin percentages despite increased operating expenses [44][45] Question: What is the status of the phase 4 trial for Cortrophin? - The phase 4 trial is progressing, but results will not be available by the time the new sales force is fully deployed [68] Question: How is the company addressing patient access for ILUVIEN? - The company is navigating market access challenges through alternative access channels and is focused on growing awareness of ILUVIEN [70][71] Question: What is the product cadence for generics? - ANI plans to maintain a strong cadence of 10 to 15 product launches annually to support growth in the generics business [72]

Financial Results - Teva Pharmaceutical Industries Ltd. is set to release its second-quarter 2025 financial results on July 30, expecting earnings of 62 cents and sales of approximately $4.29 billion [1] Generics Business Performance - Teva's generics business has shown a rebound with a 5% increase in revenue across regions, and the company anticipates five new product launches from its top-three global portfolio by 2027 [1] - The first quarter of 2025 is expected to demonstrate the strongest year-over-year growth for the generics business, despite rising competition affecting the generic Revlimid's impact [2][3] Prescription Growth - Prescription volumes for Austedo have increased by approximately 19% year-to-date, while Uzedy prescriptions rose by about 21% in the second quarter of 2025 and 17% in the first quarter [4] Future Outlook - Analysts suggest that 2025 may represent a low point for EBITDA, with cost-saving measures and efficiency improvements anticipated to benefit profits starting in 2026 [5] - Teva's branded drug business is expected to gain more influence, with a long-acting injectable version of olanzapine launching in late 2026 and a $5 billion innovative medicines franchise projected to be operational by 2030 [5] - Teva is not expected to face significant loss of exclusivity issues until well into the 2030s, which supports a case for a higher valuation multiple [6]

Company Overview - ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [2] - The company aims to deliver sustainable growth through its Rare Disease business, Generics business, and Brands business [2] Recent Developments - Nikhil Lalwani, President and CEO of ANI Pharmaceuticals, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8, 2025, in Boston, MA [1]

Financial Data and Key Metrics Changes - The company provided guidance for 2025 revenues between $768 million and $793 million, representing a year-over-year growth of approximately 25% to 29% [4][5] - Adjusted non-GAAP EBITDA guidance for 2025 is between $195 million and $205 million [4] - Q1 2025 revenues reached a record $197 million with adjusted non-GAAP EBITDA of $51 million [6] Business Line Data and Key Metrics Changes - The rare disease segment is the primary growth driver, with Cortrophin Gel expected to generate $265 million to $274 million in 2025, reflecting a year-over-year growth of 384% to 38% [8][9] - Generic revenues reached a record high of $98.7 million in Q1 2025, driven by successful new product launches [8] - The generics business is expected to sustain high single-digit to low double-digit growth, with a mid double-digit growth forecast for 2025 [37] Market Data and Key Metrics Changes - The ACTH market, which includes Cortrophin Gel, is projected to grow to $792 million in 2025, with a 16% growth rate [16] - The addressable market for Cortrophin Gel is significantly larger than the current patient population, indicating substantial growth potential [19][20] Company Strategy and Development Direction - The company aims to reinvest cash flows from generics and established brands into the rare disease business, which is expected to account for approximately half of 2025 revenues [4][36] - The acquisition of Alimera is intended to expand the rare disease business and align with the company's M&A strategy [24][32] - The company is focusing on expanding the adoption of Cortrophin Gel in targeted specialties and addressing sales factors impacting ILUVIEN and YUTIQ [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning, with over 90% of revenues coming from U.S.-manufactured products and minimal reliance on China [5] - The management highlighted the strong growth momentum in the rare disease segment, particularly for Cortrophin Gel, and the ongoing investment in R&D to support this growth [20][23] Other Important Information - The company has a healthy balance sheet with $150 million in cash and a net leverage of 2.7 turns [4][38] - The generics business launched 17 products in 2024, including two competitive generic therapy products with exclusivity [33] Q&A Session Summary Question: What is the growth outlook for Cortrophin Gel? - Management indicated that Cortrophin Gel is on a strong multiyear growth trajectory, with significant headroom for expansion in its addressable market [19][20] Question: How is the company addressing the sales impact on ILUVIEN and YUTIQ? - The company is focusing on capturing larger opportunities in diabetic macular edema and chronic noninfectious uveitis, while also expanding the sales team to drive growth [38] Question: What are the priorities for 2025? - The company outlined four key priorities: expanding Cortrophin Gel adoption, addressing sales factors for ILUVIEN and YUTIQ, sustaining generics momentum, and expanding the rare disease business through M&A [38]

Core Viewpoint - ANI Pharmaceuticals, Inc. has received FDA approval for a new prefilled syringe format of Purified Cortrophin® Gel, enhancing patient administration convenience and reflecting the company's commitment to rare disease therapies [1][2]. Product Details - The new prefilled syringe will be available in two single-dose options: 40 USP units/0.5 mL and 80 USP units/mL, alongside existing vial formats of 5 mL and 1 mL [1]. - Cortrophin Gel is indicated for various conditions, including acute gouty arthritis, rheumatoid arthritis, systemic lupus erythematosus, and severe allergic and inflammatory conditions [4]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing and commercializing innovative therapeutics, particularly in rare diseases, ophthalmology, rheumatology, nephrology, neurology, and pulmonology [6]. - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business [6].

Financial Data and Key Metrics Changes - The company reported record fourth quarter and full year 2024 results, with total revenues of $190.6 million, representing a year-over-year increase of 45% on an as-reported basis and 24% on an organic basis [10][38] - Adjusted non-GAAP EBITDA for the fourth quarter was $50 million, compared to $30.2 million in the prior year period, reflecting strong operational performance [43] - The company raised its 2025 revenue guidance to $756 million to $776 million, representing growth of 23% to 26% over 2024 [8][44] Business Line Data and Key Metrics Changes - Rare disease was the primary driver of growth, with Cortrophin Gel generating close to $200 million in sales in its third year since launch [9] - Revenues from rare disease more than doubled to $87 million in the fourth quarter, with Cortrophin Gel revenues at $59.4 million, up 42% from the prior year [39] - The generics business delivered $78.6 million in revenues, an increase of 9% over the fourth quarter of 2023, driven by operational excellence and new product launches [20][40] Market Data and Key Metrics Changes - The overall ACTH market is expected to have grown about 25% to approximately $660 million in 2024, with Cortrophin Gel's growth contributing significantly [27] - The addressable patient population for ILUVIEN and YUTIQ is estimated to be approximately six to ten times higher than the current number of patients on therapy, indicating substantial growth potential [63] Company Strategy and Development Direction - The company aims to broaden its presence in the rare disease space, as evidenced by the acquisition of Alimera Sciences [9] - The strategic rationale for acquiring Alimera includes leveraging its rare disease infrastructure to unlock the potential of Iluvien and YUTIQ [12] - The company plans to continue investing in R&D and expanding its sales force to drive growth in both rare disease and generics segments [54][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for Cortrophin Gel and the overall ACTH market, despite current market access challenges for ILUVIEN and YUTIQ [63][84] - The company anticipates a typical Q4 to Q1 decline in sales for Cortrophin Gel due to prescription reauthorizations, followed by strong sequential growth in subsequent quarters [44][64] - Management highlighted the importance of addressing unmet needs in autoimmune disorders and inflammatory diseases, which could significantly expand the addressable market for Cortrophin Gel [28] Other Important Information - The company has taken steps to enhance supply security for ILUVIEN and YUTIQ, including extending partnerships with contract manufacturers and upgrading manufacturing capabilities [15][17] - The company is also focused on improving patient and physician convenience, with plans to launch a prefilled syringe for Cortrophin Gel in the second quarter of 2025 [30][31] Q&A Session Summary Question: Business development and M&A capacity - Management indicated a thoughtful approach to leverage ratios, historically keeping it under three, and expressed intent to pursue additional business development and M&A without straining the balance sheet [52][53] Question: Gout's contribution to Cortrophin sales - Management noted that approximately 15% of Cortrophin Gel's volume currently comes from gout, which serves as a gateway indication for new prescribers [55][56] Question: Access issues for ILUVIEN and YUTIQ - Management explained that access issues stem from inadequate funding for patient assistance programs, but remains confident in the long-term growth prospects for both products [62][84] Question: Seasonality impact on Cortrophin - Management acknowledged typical Q4 to Q1 dynamics affecting Cortrophin sales but noted strong early momentum in new patient starts [64] Question: Transitioning supply from EyePoint to Siegfried - Management confirmed that they are building up inventory for ILUVIEN and YUTIQ to ensure supply security during the transition and are committed to maintaining patient access [71][73]